Summary of Sino Biopharmaceutical Conference Call Company Overview - **Company**: Sino Biopharmaceutical (1177.HK) - **Industry**: Pharmaceutical and Biotechnology Key Points Licensing Agreement - Sino Biopharmaceutical has entered into a licensing agreement with Sanofi for the global rights to rovadicitinib, a first-in-class JAK/ROCK inhibitor - The deal includes upfront payments of **US$135 million**, potential milestone payments of up to **US$1.395 billion**, and tiered sales royalties in the double digits - Ravadicitinib was approved for commercialization in China for myelofibrosis in **February 2026** and is in phase 3 trials for chronic graft-versus-host disease (cGVHD) in China, with FDA approval for phase 2 trials in the US - This agreement marks a significant milestone for Sino Biopharmaceutical in its globalization efforts, as it is the first licensing-out deal with a multinational corporation (MNC) [1][2] Clinical Development and Market Potential - cGVHD and myelofibrosis are relatively small indications in the US, with prevalences of approximately **14,000** and **19,000** respectively - Ravadicitinib shows promising potential as a treatment for cGVHD, with a best overall response (BOR) of **86.4%** compared to **74%-76%** for other therapies, and a failure-free survival rate of **85.2%** at 12 months versus **56%** for belumosudil - The safety profile of rovadicitinib is also favorable, with a discontinuation rate of **4%** compared to **6%-16%** for peers [2] Business Development Strategy - The management indicated a focus on retaining China rights for key therapeutic areas (TAs) such as oncology and hepatitis, while opting to license out global rights for assets like rovadicitinib due to commercial challenges in rare diseases in China - The business development strategy includes: 1. Collaborating with large MNCs for assets with global potential 2. Flexible collaboration modes for early-stage assets 3. Exploring emerging markets for mature assets like biosimilars - Key assets with licensing opportunities are expected to have significant data readouts in **2026** [3] Financial Estimates and Valuation - Earnings estimates for **2025-2028** remain largely unchanged, with an increase in the probability of success (PoLS) for rovadicitinib from **50%** to **100%** - The 12-month target price (TP) for Sino Biopharmaceutical has been adjusted slightly to **HK$8.02** from **HK$7.90** [6][8] Risks and Challenges - Key downside risks include: 1. Broader price cuts on the generics portfolio 2. Delays in regulatory approvals for key products 3. Low returns on R&D investments due to resource allocation issues 4. Below-expectation ramp-up of innovative drugs [8] Market Performance - Current market cap is **HK$107.1 billion** (approximately **US$13.7 billion**) - The stock price is currently at **HK$5.71**, indicating an upside potential of **40.5%** to the target price [10] Additional Insights - The agreement with Sanofi is expected to create commercial synergies with Sanofi's existing GVHD portfolio, which includes products like Sarclisa and Rezurock, generating sales of approximately **€588 million** and **€490 million** respectively in **2025** [1]

Core Insights - The European Medicines Agency (EMA) has provided positive recommendations for new drug approvals from Sanofi (SNY.US) and Insmed (INSM.US) during its recent meeting [1][2] - Sanofi's drug Wayrilz (rilzabrutinib) has been recommended for the treatment of immune thrombocytopenia, while Insmed's Brinsupri is supported for treating non-cystic fibrosis bronchiectasis in patients aged 12 and older [1][2] - Sanofi's application for Rezurock for chronic graft-versus-host disease (cGVHD) was not positively reviewed, prompting the company to seek a re-evaluation [2] Sanofi - Wayrilz has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) based on the successful LUNA Phase 3 clinical trial [1] - The company expressed disappointment over the negative opinion for Rezurock, which is already available in several countries including the U.S. [2] - Sanofi's executive vice president stated the commitment to work closely with EMA to bring the therapy to EU patients [2] Insmed - Brinsupri, an oral therapy, is poised to become the first approved treatment for non-cystic fibrosis bronchiectasis in the EU if the European Commission approves the CHMP recommendation [1] Other Companies - Roche (RHHBY.US) and Biogen (BIIB.US) received CHMP support for Gazyva (Gazyvaro) for treating specific types of lupus nephritis [2] - Regeneron Pharmaceuticals (REGN.US) is expected to gain EU approval for Libtayo as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma [2] - Agios (AGIO.US) received a positive opinion for Pyrukynd (mitapivat) for treating anemia related to adult α or β thalassemia [3] - Other companies with supported indication expansions include Bristol-Myers Squibb (BMY.US), Pfizer (PFE.US), Johnson & Johnson (JNJ.US), and Novartis (NVS.US) [3]